[Event Report] The First Sub-committee on AMR of the Nikkei Asia Africa Conference on Communicable Diseases – Asia Africa Medical Innovation Consortium (AMIC) (January 22, 2020)
date : 2/11/2020
Tags: AMR
Nikkei Inc. and AMR Alliance Japan (Secretariat: Health and Global Policy Institute (HGPI)) jointly held the First Sub-committee on AMR of the Nikkei Asia Africa Conference on Communicable Diseases – Asia Africa Medical Innovation Consortium (AMIC).
At this first sub-committee, participants from academia, the Government, industry and civil society discussed potential policy options to ensure sustainable research and development (R&D) for antimicrobials.
Participants agreed to continue to discuss the state of the antimicrobial market in working groups toward the eventual formulation of a concrete proposal on ways to incentivize antimicrobial R&D in the future.
■Overview
Date and time: Wednesday, January 22, 2020
Organizer: AMR Alliance Japan (Secretariat: HGPI)
■Program
The role of the AMR sub-committee
Mitsuru Miyata (Adviser, Medical and Healthcare Division, Nikkei Business Publications, Inc.)
Shigeru Omi (President, Japan Community Health care Organization (JCHO) / Regional Director Emeritus, Regional Office for the Western Pacific (WPRO), World Health Organization (WHO))
AMR Alliance Japan
Ryoji Noritake (CEO, Board Member, Health and Global Policy Institute (AMR Alliance Japan Secretariat))
Kazuhiro Tateda (President, The Japanese Association for Infectious Diseases / President, The Japanese Society for Clinical Microbiology / Professor, Department of Microbiology and Infectious Diseases, Toho University)
Discussion —Policy options to revitalize the antimicrobial industry
From the perspective of the Cabinet Secretariat:
Hiroyuki Noda (Councilor, Coordination Office of Measures on Emerging Infectious Diseases, Office of Pandemic Influenza and New Infectious Diseases Preparedness and Response, Cabinet Secretariat)
From the perspective of the Ministry of Health, Labour and Welfare:
Manami Yanagawa (Chief, Tuberculosis and Infectious Diseases Control Division, Ministry of Health, Labour and Welfare (MHLW))
From the perspective of the pharmaceutical industry
Takeo Morooka (Executive Officer, Head of Health Policy and Corporate Support, MSD K.K.) Takuko Sawada (Executive Vice President, Shionogi & Co., Ltd.)
Chairs:
Shigeru Omi (President, Japan Community Health care Organization (JCHO) / Regional Director Emeritus, Regional Office for the Western Pacific (WPRO), World Health Organization (WHO))
Kazuhiro Tateda (President, The Japanese Association for Infectious Diseases / President, The Japanese Society for Clinical Microbiology / Professor, Department of Microbiology and Infectious Diseases, Toho University)
Facilitator:
Ryoji Noritake (CEO, Board Member, Health and Global Policy Institute (AMR Alliance Japan Secretariat))
日本語
Top Research & Recommendations Posts
- [Announcement] HGPI Joins Alliance for Transformative Action on Climate and Health (April 22, 2024)
- [Announcement] A Significant Step Towards the Building a Green Healthcare System: Support for the Formal Expression of Interest by the Japanese Government Delegation to the ATACH at the Executive Board Meeting of the WHO (February 16, 2024)
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
- [Research Report] Survey of Japanese Physicians Regarding Climate Change and Health (December 3, 2023)
- [Research Report] 2019 Survey on Healthcare in Japan
- [Policy Recommendations] Obesity Control Promotion Project 2023 “The Next Steps for Engaging and Cooperating with Patients, Citizens, and Communities for Implements of Obesity Control Measurements” (April 8, 2024)
- [Event Report] Planetary Health Expert Meeting Aiming for Sustainable Healthcare: Learning from the Impact of Environmental Pollution and Medical Waste During the Pandemic (February 16, 2024)
- [Publication Report] Developing and Expanding Cardiovascular Disease Control Plans in Each Prefecture – Challenges and Good Examples for Cardiovascular Disease Control (September 7, 2023)
- [Public Comment Submission] Opinions Regarding the Proposed “National Action Plan on Antimicrobial Resistance 2023-2027 (Draft)” (March 16, 2023)
- [Report and Recommendations] Discussion Points in Healthcare DX Project Expert Panel Meeting (April 2, 2024)
Featured Posts
-
2024-04-22
[Registration Open] (Hybrid Format) Intractable Disease Day Symposium: Future Measures for Intractable Diseases from the Perspectives of Patients and Citizens (May, 23 2024)
-
2024-04-23
[Registration Open] (Webinar) The 125th HGPI Seminar: Progress and Prospects for Domestic Measures on Health Problems Caused by Alcohol (May 24 , 2024)
-
2024-04-30
[Event Report] Non-partisan Diet Member Briefing – 30-minute Health Policy Update: “Community Development for Senior Health: From Establishing Evidence to Social Implementation” (April 23, 2024)
-
2024-05-02
[Event Report] The 123rd HGPI Seminar – The Current Situation and Future Prospects for Epilepsy in Japan and Around the World (March 6, 2024)
-
2024-05-09
[Registration Open] The Health Policy Academy the 13th Session